We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
高通量血液透析治疗慢性肾衰竭尿毒症的疗效及对尿毒症毒素、免疫球蛋白及肺功能指标的影响
- Authors
娄占本; 热沙来提古·白和提亚尔; 麦合木提江·库迪热提; 古丽鲜·热依木; 纪振伟
- Abstract
Objective: To explore the effect of high flux hemodialysis(HFHD) on chronic renal failure uremia and its influence on uremic toxin, immunoglobulin and pulmonary function index. Methods: A total of 90 uremic patients with chronic renal failure, who were admitted to the First People’s Hospital of Kashgar from January 2012 to March 2017, were selected and were randomly divided into control group(n=45) and observation group(n=45). The control group was treated with hemodiafiltration(HDF), the observation group was treated with HFHD. Both groups were treated with dialysis for one month. The remission of symptoms and the levels of uremic toxin, immunoglobulin and pulmonary function indexes before and after dialysis were compared between the two groups. The occurrence of related complications were recorded. Results: The remission rate of observation group was 91.11% after dialysis treatment,which was higher than 73.33% in the control group(P<0.05). The levels of serum phosphorus(P-), potassium(K+), parathyroid hormone(PTH) andβ2-microglobulin(β2-MG) in the two groups after dialysis were significantly lower than those before dialysis. The level of serum calcium(Ca2+) was significantly higher than that before dialysis(P<0.05). There were no significant differences in the levels of K+, Ca2+, Pand other uremic toxins between the observation group and the control group after dialysis(P>0.05). The levels of PTH and β2-MG in the observation group after dialysis were significantly lower than those in the control group(P<0.05). After dialysis, the levels of Ig M,Ig A and Ig G in the two groups were higher than those before dialysis, the observation group was higher than the control group(P<0.05).After dialysis, the residual air volume(RV) in both groups was lower than that before treatment, and the maximum vital capacity(FVC),vital capacity(VC) and total lung volume(TLC) were higher than those before treatment, and the RV in the observation group was lower than that in the control group, the FVC, VC and TLC were higher than those of the control group(P <0.05). The incidence of complications in the observation group was 8.89%(4/45), which was lower than 24.44% in the control group(P<0.05). Conclusion:HFHD, in the treatment of patients with chronic renal failure uremia, can remove uremic toxin safely and effectively, alleviate clinical symptoms, and improve immune function and lung function of patients.
- Publication
Progress in Modern Biomedicine, 2019, Vol 19, Issue 10, p1973
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2019.10.037